Consequently, to produce durable anticancer responses, immunotherapy based on PD-1/PD-L1 inhibition is used in conjunction with other available therapeutic options, including CTLA-4 blockade, cancer vaccines, target-based small molecule inhibitors (SMIs) and agonist antibodies (12). The gene discussed is CD274; the disease is cancer.